Drugs / CAR-T Therapy
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07033299 | Jul 2025 → Dec 2026 expected | anti-neutrophil cytoplasmic antibody-associated vasculitis | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06752785 | Oct 2024 → Dec 2027 expected | acute lymphoblastic leukemia | Guangzhou Women and Children's Medical Center | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06836505 | Dec 2024 → Dec 2027 expected | desmoplastic small round cell tumor, neuroblastoma | Sun Yat-sen University Cancer Center | Recruiting | No outcome recorded |
Press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-03-03 | CARsgen Therapeutics Co., Ltd. | CARsgen’s Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA carsgen.com ↗ |
| 2025-02-28 | CARsgen Therapeutics Co., Ltd. | CARsgen’s Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in a Patient with Autoimmune Disease carsgen.com ↗ |
| 2025-01-20 | CARsgen Therapeutics Co., Ltd. | CARsgen’s Allogeneic CD38 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial carsgen.com ↗ |
| 2025-01-13 | CARsgen Therapeutics Co., Ltd. | CARsgen’s Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial carsgen.com ↗ |
| 2024-12-31 | CARsgen Therapeutics Co., Ltd. | CARsgen Announces the Initiation of an Investigator-Initiated Trial for an Allogeneic CD19/CD20 CAR-T Therapy carsgen.com ↗ |
| 2024-03-01 | CARsgen Therapeutics Co., Ltd. | NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma carsgen.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06836505 ↗ |
| Modality | Cell therapy | “CD19/CD22 CAR-T cell therapy” NCT06752785 ↗ |
| Route | Intravenous | “Cell intravenous infusion” NCT06752785 ↗ |
| Target | CD19 | “CAR-T cells targeting the CD19/CD22 target” NCT06752785 ↗ |
| Target | CD22 | “CAR-T cells targeting the CD19/CD22 target” NCT06752785 ↗ |